IP Verse

Amylin Pharmaceuticals competitive analysis

Loading summary...

Latest patents of Amylin Pharmaceuticals opposed by its competitors

Explore Amylin Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 30, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2341905
Sep 13, 2023Sustained Release Formulations Using Non-Aqueous Carriers1
EP2347762
May 8, 2019Exendin For Treating Diabetes And Reducing Body Weight2

Latest PTAB cases involving Amylin Pharmaceuticals

Discover the latest PTAB cases involving Amylin Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 3, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Amylin Pharmaceuticals

IPR2016-00348Dec 16, 2015SANOFI AVENTISAMYLIN PHARMACEUTICALSInstitution Denied
IPR2016-00353Dec 16, 2015SANOFI AVENTISAMYLIN PHARMACEUTICALSTerminated-Settled
IPR2016-00354Dec 16, 2015SANOFI AVENTISAMYLIN PHARMACEUTICALSTerminated-Settled
IPR2016-00355Dec 16, 2015SANOFI AVENTISAMYLIN PHARMACEUTICALSTerminated-Settled

Peer Comparison New

IP litigation analysis comparing Amylin Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 30, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
AMYLIN PHARMACEUTICALS - 3 - 4
GENERICS UK214 - - -
INSTONE7 - - -
SANOFI AVENTIS - - 8 -